Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 30, 2025Clinical Nephrology

Anti-nephrin antibodies in minimal change disease: Case report series

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMaša KnehtlNPNejc PikoTPTadej Petreski

Discussion

Loading...

Member takes

Overview

Case reports reveal autoantibodies in minimal change disease, suggesting rituximab for relapsing patients with treatment resistance.

Key Points

  • Autoantibodies linked to minimal change disease support its autoimmune nature, indicating further investigation is necessary.
  • The administration of rituximab offers a new therapeutic avenue for patients showing treatment resistance or adverse effects.
  • Observational analysis of case reports across several patients highlights varying responses to anti-B-cell therapy.
  • Further research may clarify the role of autoantibodies in treatment strategies for minimal change disease.

Cite This Study

Knehtl et al. (2025) studied this question.

synapsesocial.com/papers/692b9d8d1d383f2b2a3799bfhttps://doi.org/10.5414/cnp104s12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti-CD20 therapies and anti-nephrin autoantibodies in IgA nephropathy with minimal change disease2026
  2. 2TREATMENT OF MINIMAL CHANGE DISEASE IN ADULTS: CURRENT PRACTICE AND FUTURE DIRECTIONS – A NARRATIVE LITERATURE REVIEW2025
  3. 3When Minimal Becomes Massive: A Case Report of Childhood-Onset Minimal Change Disease Marching to End Stage Renal Disease Despite Modern Immunotherapy2026
  4. 4Serum Factors in Primary Podocytopathies2025
  5. 5A New Hope for Treating Podocytopathies — Emerging Role of Anti-Nephrin Antibody2026